The KEYNOTE-024 trial demonstrated that pembrolizumab, compared to platinum-based chemotherapy, significantly extended median PFS in previously untreated NSCLC patients with a PD-L1 tumor proportion score of at least 50% and no EGFR or ALK genetic alterations (10.3 vs. 6.0 HR 0.50). Here, ALK is linked to neoplasm.